{
    "id": 26194,
    "cites": 7,
    "cited_by": 0,
    "reference": [
        "Aitken, Murray, Ernst R. Berndt, David Cutler, Michael Kleinrock, and Luca Maini. 2016. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Has the Era of Slow Growth for Prescription Drug Spending Ended?\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Health Affairs 35(9):1595\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c1603. Aitken, Murray L., and Michael Kleinrock. 2018. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Medicines Use and Spending in the U.S.: A Review of 2017 and Outlook to",
        ".\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Parsippany, NJ: IQVIA Institute for Human Data Science. https://www.iqvia.com/-/media/iqvia/pdfs/institute-reports/medicine-use-andspending -in-the-us-a-review-of-2017-and-outlook-to2022. pdf. Alpern, Jonathan D., William M. Stauffer, and Aaron S. Kesselheim. 2014. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093High-Cost Generic Drugs\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009dImplications for Patients and Policymakers.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d New England Journal of Medicine",
        "(20): 1859\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c1862. Berndt, Ernst R., and Murray L. Aitken. 2011. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Brand Loyalty, Generic Entry and Price Competition in Pharmaceuticals in the Quarter Century after the 1984 Waxman-Hatch Legislation.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d International Journal of the Economics of Business 18(2): 177\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c201. http://proxy.uchicago.edu/login?url=http://search.ebscohost .com/login.aspx?direct=true&db=eoh&AN=1262154&site=ehostlive &scope=site. Berndt, Ernst R., Rena M. Conti, and Stephen J. Murphy. 2017. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Landscape of US Generic Prescription Drug Markets,",
        "-2016.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d National Bureau of Economic Research, Working Paper No. 23640. \u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009d\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009d\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009d. 2018. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Generic Drug User Fee Amendments: An Economic Perspective.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Law and the Biosciences 5 (1):",
        "\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c141. Berndt, Ernst R., and Pierre Dubois. 2016. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Impacts of Patent Expiry and Regulatory Policies on Daily Cost of Pharmaceutical Treatments: OECD Countries, 2004-2010.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d International Journal of the Economics of Business 23(2):",
        ". Berndt, Ernst R., Richard Mortimer, Ashoke Bhattacharjya, Andrew Parece, and Edward Tuttle. 2007. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Authorized Generic Drugs, Price Competition, and Consumers\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0084\u00a2 Welfare.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Health Affairs",
        "1.68 1.00 1.00 2.00 4.81 2.00 1.00 6.00 6.01 4.00 1.00 9.00 4.81 3.00 1.00 6.00 6.38 4.00 2.00 9.00 Overall 1.93 1.00 1.00 2.00 4.72 3.00 1.00 6.00 4.78 3.00 1.00 6.00 4.90 3.00 2.00 6.00 6.94 5.00 2.00 10.00 < 15 years 15-19 years 20-24 years 25-34 years 35+ years TABLE 4: MEAN, MEDIAN AND INTERQUARTILE RANGE OF MOLFORM ANNUAL REVENUES OVER ALL FORMULATIONS AND BY FORMULATION SOURCE: Authors' calculations based on IQVIA NSP data, 2004Q4 - 2016Q3. NOTES: Revenues collected at the mnf-molform level for each period. YEAR Mean Median 25-pctile 75-pctile Mean Median 25-pctile 75-pctile Mean Median 25-pctile 75-pctile Mean Median 25-pctile 75-pctile"
    ]
}